Paper Details

  1. Home
  2. Paper Details

Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy.

Author: Coelho-Dos-ReisJordana Grazziela Alves, Costa-RochaIsmael Artur da, FonsecaLucy Ana Dos Santos, FradicoJordana Rodrigues Barbosa, Martins-FilhoOlindo Assis, RibeiroIsabela Gomes, SilvaLuciana Diniz, StancioliRhaissa Carvalho Said, TeixeiraRosângela, Teixeira-CarvalhoAndréa

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

DAAs, a new treatment for hepatitis C, allow us to observe immune system changes caused by rapid viral replication suppression. A study of 50 patients showed that DAA treatment significantly reduced levels of several biomarkers associated with inflammation. The study also found that high ALT levels, low platelet count, and cirrhosis at the start of treatment were associated with delayed immune response recovery. These findings provide valuable insights into the immune restoration process triggered by DAA therapy.
Paper Details　
Original Abstract of the Article :
The HCV treatment with DAAs has offered a unique opportunity to analyze the changes in the immune system caused by the rapid inhibition of viral replication. We sought to analyze the kinetics profiles of serum biomarkers (LuminexTM) in fifty patients with chronic hepatitis C enrolled in a longitudin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.antiviral.2021.105073

データ提供：米国国立医学図書館（NLM）

A Glimpse into the Immune Response After Hepatitis C Treatment

The field of virology is constantly evolving, and hepatitis C is no exception. This research delves into the intricate workings of the immune system after patients receive treatment for chronic hepatitis C. They used a technique called LuminexTM, which is like a detective tool that helps analyze a wide range of immune biomarkers in the blood. The study focused on analyzing changes in these biomarkers over time, from before treatment to several weeks after treatment. The results were quite fascinating, showing a clear shift in the immune system's response. This research provides a deeper understanding of how the body fights off hepatitis C and how treatment affects the immune system's journey back to equilibrium.

A Symphony of Immune Biomarkers

The researchers observed a clear overproduction of immune biomarkers in patients before treatment. This is like a symphony of immune cells, all playing their part in fighting the virus. But when the treatment kicked in, the symphony began to change. Certain biomarkers like CXCL8, CCL4, and IL-6 decreased rapidly in the first few weeks, while others like CCL3, CCL2, and CCL5 took a bit longer to decrease. These findings offer a detailed glimpse into how the immune system reacts to the new era of direct-acting antiviral therapy.

Balancing the Immune System

Understanding these immune changes can have significant implications for patient care. The study identified factors like high ALT levels, low platelet counts, and liver cirrhosis as indicators of a delayed immune response. This information could help healthcare professionals tailor treatment strategies to each patient's unique situation, ensuring a smoother transition back to health.

Dr.Camel's Conclusion

This research provides valuable insights into the intricate dance between the immune system and hepatitis C, revealing how treatment affects this delicate balance. The study's findings, like a desert oasis providing a haven for weary travelers, are a beacon of hope, offering a roadmap for better patient care and a glimpse into a future where hepatitis C is no longer a looming threat.

Date :
  1. Date Completed 2021-12-10
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

33887350

DOI: Digital Object Identifier

10.1016/j.antiviral.2021.105073

Related Literature

Article Analysis
・Effects of simeprevir・Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.